Poly-ICLC preconditioning protects the blood-brain barrier against ischemic injury in vitro through type I interferon signaling

J Neurochem. 2012 Nov;123 Suppl 2(Suppl 2):75-85. doi: 10.1111/j.1471-4159.2012.07946.x.

Abstract

Preconditioning with a low dose of harmful stimulus prior to injury induces tolerance to a subsequent ischemic challenge resulting in neuroprotection against stroke. Experimental models of preconditioning primarily focus on neurons as the cellular target of cerebral protection, while less attention has been paid to the cerebrovascular compartment, whose role in the pathogenesis of ischemic brain injury is crucial. We have shown that preconditioning with polyinosinic polycytidylic acid (poly-ICLC) protects against cerebral ischemic damage. To delineate the mechanism of poly-ICLC protection, we investigated whether poly-ICLC preconditioning preserves the function of the blood-brain barrier (BBB) in response to ischemic injury. Using an in vitro BBB model, we found that poly-ICLC treatment prior to exposure to oxygen-glucose deprivation maintained the paracellular and transcellular transport across the endothelium and attenuated the drop in transendothelial electric resistance. We found that poly-ICLC treatment induced interferon (IFN) β mRNA expression in astrocytes and microglia and that type I IFN signaling in brain microvascular endothelial cells was required for protection. Importantly, this implicates a potential mechanism underlying neuroprotection in our in vivo experimental stroke model, where type I IFN signaling is required for poly-ICLC-induced neuroprotection against ischemic injury. In conclusion, we are the first to show that preconditioning with poly-ICLC attenuates ischemia-induced BBB dysfunction. This mechanism is likely an important feature of poly-ICLC-mediated neuroprotection and highlights the therapeutic potential of targeting BBB signaling pathways to protect the brain against stroke.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Analysis of Variance
  • Animals
  • Animals, Newborn
  • Blood-Brain Barrier / drug effects*
  • Blood-Brain Barrier / metabolism
  • Brain Infarction / drug therapy
  • Brain Infarction / etiology
  • Carboxymethylcellulose Sodium / administration & dosage
  • Carboxymethylcellulose Sodium / analogs & derivatives*
  • Carboxymethylcellulose Sodium / pharmacology
  • Cells, Cultured
  • Disease Models, Animal
  • Enzyme-Linked Immunosorbent Assay / methods
  • Gene Expression Regulation / drug effects
  • Gene Expression Regulation / genetics
  • Glucose / deficiency
  • Hypoxia / drug therapy
  • Hypoxia / metabolism
  • Infarction, Middle Cerebral Artery / complications
  • Infarction, Middle Cerebral Artery / genetics
  • Infarction, Middle Cerebral Artery / prevention & control*
  • Interferon Regulatory Factor-1 / deficiency
  • Interferon Regulatory Factor-1 / metabolism*
  • Interferon-beta / genetics
  • Interferon-beta / metabolism
  • Ischemic Preconditioning / methods*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Neuroglia / drug effects
  • Neuroprotective Agents / administration & dosage*
  • Poly I-C / administration & dosage*
  • Poly I-C / pharmacology
  • Polylysine / administration & dosage
  • Polylysine / analogs & derivatives*
  • Polylysine / pharmacology
  • RNA, Messenger / metabolism
  • Signal Transduction / drug effects*
  • Tight Junctions / drug effects
  • Tight Junctions / pathology
  • Time Factors

Substances

  • Interferon Regulatory Factor-1
  • Irf1 protein, mouse
  • Neuroprotective Agents
  • RNA, Messenger
  • Polylysine
  • Interferon-beta
  • poly ICLC
  • Glucose
  • Carboxymethylcellulose Sodium
  • Poly I-C